Login to Your Account


Pfizer seeks to boost Prevnar 13 use in adults with CAPiTA data

By Marie Powers
Staff Writer

Monday, February 24, 2014
Pfizer Inc.’s blockbuster vaccine, Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), could be poised for a big boost. Pfizer reported that its CAPiTA study met its primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription